EyeCon 2026 Banner
|Videos|August 25, 2021

RVL Pharmaceuticals: Shifting toward ocular aesthetics

COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.

JD Schaub, chief operating officer at RVL Pharmaceuticals, provides an overview of how the company has shifted toward focusing on ocular aesthetics, along with the sole purpose to fully focus on UPNEEQ®, a prescription eye drop.

See more ASCRS coverage


Latest CME